Business
Century Therapeutics Reports First Quarter Financial Results and Business Updates
CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026On track to advance CNTY‑308, Century’s CD19‑targeted CAR‑iT cell therapy, into the clinic this yearCash runway into 1Q 2029 with cash, cash equivalents, and marketable securit
About this update from Century Therapeutics, Inc.
[{"type":"image","alt":"Century Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Century Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1qMMhZqDcCAAdTlry0aLDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be","width":300,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1qMMhZqDcCAAdTlry0aLDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be","width":300,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"On track to advance CNTY‑308, Century’s CD19‑targeted CAR‑iT cell therapy, into the clinic this year","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026","length":118,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":542,"olType":false},{"type":"text","content":"PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.","length":373,"tagName":"p"},{"type":"text","content":"“We are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY-813 highlights what Century can achieve pairing our Allo-Evasion™ engineering with a scalable iPSC platform,” said Brent Pfeiffenberger, P...